CD8+ T cell responses to CMV are preserved after CD25/71 allodepletion
| . | Donor 1 B7-TPR . | Donor 2 B7-TPR . | Donor 3 B7-TPR . | Donor 4 A2-NLV . |
|---|---|---|---|---|
| Unmanipulated | 3.01% | 14.23% | 2.05% | 0.46% |
| CD25/71 | 2.52% | 8.45% | 3.98% | 0.29% |
| . | Donor 1 B7-TPR . | Donor 2 B7-TPR . | Donor 3 B7-TPR . | Donor 4 A2-NLV . |
|---|---|---|---|---|
| Unmanipulated | 3.01% | 14.23% | 2.05% | 0.46% |
| CD25/71 | 2.52% | 8.45% | 3.98% | 0.29% |
FACS analysis of 4 CMV-seropositive donors in unmanipulated PBMCs or after CD25/71 allodepletion after staining with HLA-A2 CMV pentamer. The percentage of pentamer-positive cells in the CD3+/CD8+ lymphocyte gate was expressed as a proportion of the CD8+ cells. CMV, pp65-specific HLA-A*0201-NLVPMVATV (A2-NLV) and HLA-B*0702-TPRYTGGGAM (B7-TPR).